Immatics (4A3) Stock Price & Analysis
4A3 Stock Chart & Stats
- Day’s Range
- EUR 6.37 - EUR 6.37
- 52-Week Range
- EUR 5.76 - EUR 10.15
- Previous Close
- EUR 6.41
- Volume
- N/A
- Average Volume (3M)
- 299
- Market Cap
- EUR 939.82M
- Enterprise Value
- EUR 951.55M
- Total Cash (Recent Filing)
- EUR 393.19M
- Total Debt (Recent Filing)
- EUR 14.60M
- Price to Earnings (P/E)
- ―
- Beta
- 0.60
- Next Earnings
- Nov 17, 2026 (Est.)
- EPS Estimate
- -0.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage
Very low leverage reduces solvency pressure while Immatics funds clinical development, giving the company more financial flexibility than a similarly loss-making biotech with substantial debt. This supports resilience against refinancing stress and preserves options for future capital allocation.
Fresh Development Capital
The completed equity financing materially strengthens resources available to advance Immatics’ clinical programs and platform. Funding for research, manufacturing and potential commercialization can extend execution capacity and help the company pursue its oncology pipeline without relying solely on near-term collaboration receipts.
Focused Oncology Platform
A focused PRAME-centered strategy combined with antigen discovery and T-cell receptor engineering gives Immatics a coherent platform for developing multiple cancer immunotherapies. The breadth of the targeted antigen opportunity may support pipeline expansion and strengthen the strategic value of its programs.
Bears Say
Deep Ongoing Losses
Severely negative margins show that current operating scale is far below the spending required to support the business. Until clinical programs or partnerships produce greater economic returns, persistent losses can consume capital and make earnings power difficult to assess or sustain.
High Cash Burn
Materially negative operating and free cash flow means Immatics is not currently self-funding its development activities. Continued cash burn increases dependence on financing or collaboration proceeds, constrains flexibility, and makes the durability of the business model reliant on future pipeline progress.
Clinical-stage Revenue Dependence
Because Immatics remains clinical-stage without a broad marketed-product portfolio, revenue depends mainly on partnerships, reimbursements, milestones and possible future royalties. That structure leaves operating funding tied to development progress and partner appetite rather than recurring product sales.
Immatics News
4A3 FAQ
What was Immatics’s price range in the past 12 months?
What is Immatics’s market cap?
When is Immatics’s upcoming earnings report date?
How were Immatics’s earnings last quarter?
Is Immatics overvalued?
Does Immatics pay dividends?
What is Immatics’s EPS estimate?
How many shares outstanding does Immatics have?
What happened to Immatics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Immatics?
What is the TipRanks Smart Score and how is it calculated?
Immatics Stock Smart Score
Company Description
Immatics
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Harpreet Singh
- Employees
- 704
- Website
- www.immatics.com
- Address
- Paul-Ehrlich-Strasse 15, Tübingen, BW, 72076, DE
Immatics (4A3) Earnings & Revenues
4A3 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |
